Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2021 10:55 ET | Source: Biosplice Therapeutics, Inc.

Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform

New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...